Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report | Zendy

Bixia Tang | Zendy; Xinan Sheng | Zendy; Yan Kong | Zendy; Zhihong Chi | Zendy; Lu Si | Zendy; Chuanliang Cui | Zendy; Xieqiao Yan | Zendy; Lili Mao | Zendy; Bin Lian | Zendy; Siming Li | Zendy; Xuan Wang | Zendy; Jie Dai | Zendy; Xue Bai | Zendy; Li Zhou | Zendy; Jun Guo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report

Author(s) -

Bixia Tang,

Xinan Sheng,

Yan Kong,

Zhihong Chi,

Lu Si,

Chuanliang Cui,

Xieqiao Yan,

Lili Mao,

Bin Lian,

Siming Li,

Xuan Wang,

Jie Dai,

Xue Bai,

Li Zhou,

Jun Guo

Publication year - 2018

Publication title -

chinese clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.733

H-Index - 22

eISSN - 2304-3873

pISSN - 2304-3865

DOI - 10.21037/cco.2018.06.08

Subject(s) - palbociclib , medicine , metastatic melanoma , melanoma , oncology , copy number variation , cancer research , cancer , genetics , metastatic breast cancer , gene , genome , biology , breast cancer

The mortality associated with unresectable or metastatic melanoma remains high despite of the emergence of new anti-tumor agents. In this case report, we present two metastatic melanoma patients with copy number variations (CNVs) of cyclin dependent kinase 4 (CDK4) pathway-related genes, who had failed in previous chemotherapy or immunotherapy, were treated with CDK4/6 inhibitor palbociclib and achieved tumor control for over 6 months. The copy number of CDK4, CCND1 and P16INK4a of one patient was 3.6, 3, 2 copies, and for the other patient, the copy number was 3, 2, 1 respectively. It indicates that CDK4 may be a potential target for melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research